299177-99-4

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1655-07-8 ethyl 2-oxocyclohexane carboxylate 
• 106758-67-2 (1S,2S)-2-(hydroxymethyl)cyclohexanol 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS

The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Stereoselective synthesis of novel anti-MRSA tricyclic carbapenems (trinems)

(4S)-Hydroxymethyltrinem 3 was prepared via stereoselective aldol-type reaction with optically pure (R)-2-t-butyldimethylsilyloxymethylcyclohexanone ((R)-16). (4S)-Hydroxymethyltrinem 3 was converted into various kinds of trinem derivatives with anti-MRSA activity by using the Mitsunobu reaction. (C) 2000 Elsevier Science Ltd.